Myasthenia gravis (MG) in children and adolescents to age 18 -- juvenile MG -- includes clinically significant developmental ...

HOUSE, PA — Johnson & Johnson (NYSE: JNJ) has unveiled new data demonstrating the efficacy of IMAAVY™ (nipocalimab-aahu) for the treatment of generalized myasthenia gravis (gMG). Presented at the ...

Thymoma is strongly associated with myasthenia gravis (MG), particularly at the onset of the disease 1 1. Zielinski M. Management of myasthenic patients with thymoma. Thorac Surg Clin 2011;21:47-57. .

ImmunAbs Inc., a clinical-stage biotech specializing in developing antibody therapeutics, today announced that the U.S. Food and Drug Administration has cleared its Investigational New Drug (IND ...

Additionally, there was no statistically significant differences between pre- and post-thymectomy in thymoma-associated MG (TAMG). Conclusion: Individuals with unstable MG appear to demonstrate ...

Myasthenia gravis (MG) should be subgrouped into early-onset, late-onset, thymoma, ocular, anti-MuSK, anti-LRP4 and antibody-negative MG. MG has a prevalence of 140 per million, and an annual ...

Background Myasthenia Gravis (MG) is an autoimmune disorder presenting with fatigable muscle weakness leading to potential respiratory distress. Clinical management aims to improve patient quality of ...

"Psychological assessments are essential in the management of myasthenia gravis, as the condition is frequently associated with psychiatric comorbidities such as fatigue, depression, anxiety ...

The NHS webpage on myasthenia gravis may be a good place to find out more. These organisations can give you advice and support: Myaware, 01332 290 219; Muscular Dystrophy UK, 0800 652 6352; You can ...

Evidence-based recommendations on efgartigimod (Vyvgart) for treating antibody-positive generalised myasthenia gravis in adults.. Last reviewed: 04 June 2025 Next review: This guidance will be ...

Myasthenia gravis (MG) should be subgrouped into early-onset, late-onset, thymoma, ocular, anti-MuSK, anti-LRP4 and antibody-negative MG. MG has a prevalence of 140 per million, and an annual ...